Levetiracetam Teva

Levetiracetam, the active ingredient in Levetiracetam Teva, is an antiepileptic presented as a tablet for oral use. It treats partial‑onset, generalized tonic‑clonic and myoclonic seizures in patients who require seizure control.

GNH USA supplies Levetiracetam Teva as a licensed, GDP‑compliant international pharmaceutical supplier, adhering to stringent quality standards and serving hospitals, pharmacies, and clinics worldwide. Our global distribution network ensures reliable delivery across Europe, Asia, Africa and the Americas. We provide regulatory support and documentation to facilitate import and compliance for institutional buyers.

Levetiracetam is an antiepileptic medication used to manage several seizure types. - Partial‑onset seizures: Decreases the frequency and severity of focal seizures in patients with epilepsy, improving daily functioning. - Generalized tonic‑clonic seizures: Provides effective control of bilateral convulsive seizures in both adult and pediatric populations, reducing the risk of injury. - Myoclonic seizures: Mitigates sudden, brief muscle jerks characteristic of juvenile myoclonic epilepsy, helping to maintain motor stability. - Adjunctive therapy for refractory epilepsy: Used as add‑on treatment when seizures are not adequately controlled by other agents.

Levetiracetam may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Dizziness: Sensation of light‑headedness or unsteadiness. - Fatigue: Persistent tiredness or reduced energy. - Headache: Mild to moderate cranial pain. - Irritability: Mood changes including increased agitation. - Nausea: Upset stomach or urge to vomit. - Coordination problems: Ataxia or clumsiness.

Serious or Rare Side Effects: - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Suicidal thoughts: Emergence of depressive symptoms or suicidal ideation. - Hematologic abnormalities: Unusual bruising, low blood cell counts or anemia. - Liver injury: Elevated transaminases or hepatitis. - Anaphylaxis: Rare severe allergic reaction requiring immediate medical attention.

When prescribing Levetiracetam, clinicians should consider several precautionary measures to ensure safe use. - Renal function: Adjust dose in patients with impaired kidney function. - Mood monitoring: Observe for new or worsening depression, anxiety, or suicidal thoughts. - Concomitant CNS depressants: Use caution when combined with other sedating agents. - Pregnancy: Evaluate risk‑benefit ratio; limited data available. - Driving and machinery: Advise patients to assess personal response before operating vehicles or heavy equipment. - Store at ambient temperature: Keep below 25 °C in the original container, protected from moisture and light.

Levetiracetam can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Carbamazepine: May reduce levetiracetam plasma levels, decreasing seizure control. - Phenobarbital: Similar enzyme‑inducing effect leading to lower levetiracetam concentrations. - Rifampicin: Strong inducer that can markedly lower levetiracetam exposure.

Moderate Interactions (Monitor Closely): - Valproic acid: May increase levetiracetam levels, requiring monitoring for toxicity. - Sedatives (benzodiazepines, alcohol): Additive CNS depression may enhance drowsiness. - Oral contraceptives: Possible reduction in contraceptive effectiveness; advise additional protection.